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Hyponatremia is the most common electrolyte disorder in
clinical practice. Its incidence increases with age and it is
associated with increased morbidity and mortality. Recently,
the vaptans, antagonists of the arginine vasopressin pathway,
have shown promise for safe treatment of hyponatremia.
Here we evaluated the efficacy, safety, and tolerability of oral
lixivaptan, a selective vasopressin V2-receptor antagonist,
for treatment of nonhospitalized individuals with euvolemic
hyponatremia (sodium less than 135mmol/l) in a multicenter,
randomized, double-blind, placebo-controlled, phase III study.
About half of the 206 patients were elderly in a chronic care
setting. Of these patients, 52 were given a placebo and
154 were given 25–100mg per day lixivaptan, titrated based
on the daily serum sodium measurements. Compared with
placebo (0.8mmol/l), the serum sodium concentration
significantly increased by 3.2mmol/l from baseline to day 7
(primary efficacy endpoint) with lixivaptan treatment.
A significantly greater proportion of patients that received
lixivaptan achieved normal serum sodium (39.4%) by day 7
relative to placebo (12.2%). Overall, lixivaptan was considered
safe and well-tolerated. Thus, oral lixivaptan can be safely
initiated in the outpatient setting and effectively increases
serum sodium concentrations in outpatients with euvolemic
hyponatremia.
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Hyponatremia is the most common laboratory abnormality,
occurring in up to 30% of hospitalized patients and in up to
21% of ambulatory patients.1 Hyponatremia also is more
frequently observed in elderly patients—an incidence of
18–22% has been reported in chronic care facilities, with 53%
of patients having one or more episodes of hyponatremia
over a 12-month period.2,3 As hyponatremia is associated
with multiple etiologies and underlying disease states,
diagnosis and treatment can be complex.4 Mild hyponatre-
mia is often characterized as ‘asymptomatic’. However, this
concept has been more recently challenged, and ‘asympto-
matic’ hyponatremia appears to be a misnomer.5 Patients
with chronic hyponatremia have been shown to exhibit
cognitive impairment, gait disturbances, and an increased
incidence of falls and fractures.6,7 In addition, hyponatremia
is associated with increased risk of death, even when
considered mild.8–10 Researchers have often considered
hyponatremia a marker of the severity of underlying
conditions.11 However, at least one study has demonstrated
significantly lower rates of death when hyponatremia was
managed compared with when it was uncontrolled, indicat-
ing that treatment may be beneficial.12
Hyponatremia can occur in the hypovolemic, euvolemic,
and hypervolemic states. In the euvolemic state, hypona-
tremia often results from the syndrome of inappropriate
antidiuretic hormone (SIADH).10,13 SIADH occurs when
arginine vasopressin is released despite serum hypo-osmo-
larity. This condition can be caused by the presence of
tumors, central nervous system disease, pulmonary disease,
or the use of certain drugs that act directly or indirectly on
the arginine vasopressin pathway.13
Treatment of chronic hyponatremia is challenging. Fluid
restriction and pharmacological agents, such as demeclocy-
cline, lithium, and urea, have been used.
More recently, the vaptans, a class of drugs that antagonize
the arginine vasopressin pathway, have shown promise for
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safe treatment of hyponatremia.14 Two vaptans, conivaptan, a
mixed V1/V2-receptor antagonist, and tolvaptan, an oral,
V2-selective antagonist, are approved in the United States
for the treatment of hyponatremia. Conivaptan is an
intravenously administered agent that has demonstrated
efficacy in hospitalized subjects with hyponatremia.15–17
Tolvaptan is orally administered and has demonstrated
efficacy in increasing serum sodium concentrations in phase
III studies of subjects with euvolemic or hypervolemic
hyponatremia.18 All the studies conducted with these two
agents excluded symptomatic subjects and those with serum
sodium concentrations o120 mmol/l in association with
neurological impairment, and they required initiation of
therapy in hospitalized subjects.
Lixivaptan is a selective vasopressin V2-receptor antago-
nist that blocks arginine vasopressin-mediated aquaporin
synthesis and membrane insertion.19 In phase II trials,
lixivaptan has increased water excretion, increased serum
osmolarity, and increased serum sodium concentration in
subjects with heart failure, cirrhosis, or SIADH.20–22 In this
multicenter, double-blind, placebo-controlled study (HAR-
MONY study), the efficacy, safety, and tolerability of oral
lixivaptan were evaluated for the treatment of chronic
euvolemic hyponatremia in outpatient settings that included
long-term care facilities and nursing homes. Subjects with
symptoms attributable to hyponatremia were included in the
study.
RESULTS
Subjects
A total of 206 randomized subjects (154 to lixivaptan and 52
to placebo) were included in the intent-to-treat (ITT)
population. Subject disposition is shown in Figure 1. All
subjects received at least one dose of medication except for
one in the lixivaptan group. Twenty-one percent of the
randomized population (44 subjects) was enrolled from long-
term care facilities/nursing homes, with the remainder of the
population being enrolled from a variety of settings, including
outpatient clinics, doctors’ offices, and hospitals. Overall,
approximately 83% of the subjects were enrolled in a non-
hospital setting. In all, 130 (84.4%) subjects receiving
lixivaptan and 42 (80.8%) subjects receiving placebo com-
pleted 8 weeks of treatment. The most common reasons for
discontinuation during the first 8 weeks were subject with-
drawal of consent (5.2% of subjects receiving lixivaptan and
3.8% of subjects receiving placebo), adverse events (4.5 and
11.5%, respectively), and death (2.6 and 0%, respectively). As
sufficient efficacy data had been gathered, the study was ended
once the last subject had completed a minimum of 8 weeks of
treatment. A total of 34.4% of subjects receiving lixivaptan
and 32.7% of subjects receiving placebo completed the entire
24-week period of treatment.
Baseline characteristics of the treatment groups were
generally well balanced (Table 1). A greater percentage of
white subjects were enrolled in the lixivaptan group compared
with the placebo group (81.8 vs. 67.3%). Approximately half of
the subjects were aged 65 years or older. The most common
concomitant prescription medications used by subjects were
omeprazole (31.8% of subjects in the lixivaptan group and
30.8% of subjects in the placebo group), simvastatin (18.2 and
26.9%, respectively), and amlodipine (24.0 and 17.3%,
respectively). Baseline symptoms associated with hyponatre-
mia (reported inX10% of subjects) included fatigue (40.7%),
mental slowing (27.0%), headache (19.1%), confusion
(16.7%), and irritability (16.2%). The underlying cause of
SIADH was not collected prospectively in the study. At
baseline, 4 patients (2.0%) had lung cancer, 1 (0.5%) had HIV
infection, 3 (1.5%) had a history of subarachnoid hemorrhage,
1 (0.5%) had the Guillain–Barre syndrome, 1 (0.5%) had
sarcoidosis, 48 (23.4%) had underlying hypothyroidism, and
95 (46.3%) were receiving drugs known to induce hypona-
tremia, including carbamazepine (7.8%), phenothiazines
(2.0%), selective serotonin re-uptake inhibitors (21.5%),
thiazides (7.5%), and monoamine oxidase inhibitors (10.5%).
Efficacy
Significantly greater serum sodium increases from baseline
were observed at day 7 in subjects receiving lixivaptan
compared with those receiving placebo (least-squared mean
with s.e. of 3.2. (0.5) vs. 0.8 (0.6) mmol/l; Po0.001).
Sensitivity analyses also showed significant differences be-
tween lixivaptan and placebo for the primary efficacy variable
(Po0.001 for all). A sensitivity assessment using a mixed
model repeated measures analysis also demonstrated a
2.6±0.3 mmol/l difference (least-squared mean±s.e.) be-
tween lixivaptan and placebo in changes in central sodium
Randomized (N = 206)
Allocated to lixivaptan (n = 154)
Day 7 (primary end point)
Completed 8 weeks of treatment (n = 130)* Completed 8 weeks of treatment (n = 42)*
Completed 24 weeks of treatment (n = 17)Completed 24 weeks of treatment (n = 53)
Subject withdrew consent (n = 8)
Adverse event (n = 7)
Adverse event (n = 6)
Death (n = 4)
Investigator withdrew subjects (n = 2)
Lack of efficacy (n = 1)
Lack of efficacy (n = 1)
Protocol violation (n = 1)
Subject withdrew consent (n = 2)
Other (n = 1)
Analyzed for primary efficacy end point
(n = 154)
Analyzed for primary efficacy end point
(n = 52)
Excluded from analysis (n = 0)
*Blinded study treatment was discontinued by sponsor once the last randomized subject
completed week 8. All subjects were to enter a 30-day follow-up period following cessation
of treatment. 
Excluded from analysis (n = 0)
Discontinued study during first 8 weeks
(n = 23)
Discontinued study during first 8 weeks
(n = 10)
Day 7 (primary end point)
Central sodium assessed in 142
subjects
Central sodium assessed in 49
subjects
Allocated to placebo (n = 52)
Received placebo (n = 52)Received lixivaptan (n = 153)
Did not receive lixivaptan (n = 1)
Figure 1 | Subject disposition.
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from baseline to day 7 (Po0.001). Additional sensitivity
analyses showed that the mean increase in serum sodium
concentrations from baseline to day 7 was significantly greater
(Po0.05) in the lixivaptan group compared with placebo
regardless of sex or age (X65 years or o65 years).
Numerically greater increases in serum sodium levels occurred
in patients with more severe hyponatremia at baseline.
Within 8 h of lixivaptan administration, serum sodium
concentrations were significantly higher in the lixivaptan
group compared with the placebo group (Figure 2).
Lixivaptan remained numerically superior to placebo at all
subsequent study visits. The mean increase in central serum
sodium from baseline to the end of treatment (4.0 vs.
1.4 mmol/l) was significantly different between groups
(P¼ 0.002) for the ITT population using observed values
(OV). Importantly, after discontinuation of the study drug,
serum sodium concentrations in the lixivaptan group
declined over the ensuing week to values similar to baseline.
The least-squared mean (s.e.) daily normalized change in
area under the concentration curve (AUC) for central serum
sodium levels from baseline to day 3 (AUC0–3), baseline to
day 28 (AUC028), and baseline to day 56 (AUC0–56) was
significantly higher for subjects receiving lixivaptan than for
subjects receiving placebo (P¼ 0.042, P¼ 0.004, and
P¼ 0.004, respectively; Figure 3). Sensitivity analyses also
found significantly greater AUC028 for subjects receiving
lixivaptan compared with those receiving placebo (Pp0.005
for all).
By day 7, 39.4% of subjects receiving lixivaptan and 12.2%
of subjects receiving placebo had achieved normalized serum
sodium concentrations (Po0.001). At the end of treatment,
Table 1 | Subject demographics and baseline characteristics
Demographic parameter
Lixivaptan
(n=154)
Placebo
(n=52)
Age, years
Mean (s.d.) 66.6 (14.1) 62.7 (13.6)
Range 24–98 29–90
Subjects aged X65 years, n (%) 87 (56.5) 24 (46.2)
Male subjects, n (%) 73 (47.4) 27 (51.9)
Race, n (%)
White 126 (81.8) 35 (67.3)
Asian 18 (11.7) 8 (15.4)
Black 7 (4.5) 8 (15.4)
Othera 3 (1.9) 1 (1.9)
Hispanic ethnicity 19 (12.3) 8 (15.4)
Region, n (%)
North America 122 (79.2) 37 (71.2)
India 17 (11.0) 7 (13.5)
Europe/Israel 8 (5.2) 4 (7.7)
South America 7 (4.5) 4 (7.7)
Body mass index, kg/m2 n=149 n=49
Mean (s.d.) 26.4 (5.7) 26.9 (6.3)
Range 16.0–41.7 17.1–41.9
Local serum sodium, mmol/l (s.d.)b
Mean (s.d.) 129.7 (4.4) 129.9 (4.3)
Range 113.0–134.0 111.8–134.5
Central serum sodium, mmol/l (s.d.)c
Mean (s.d.) 131.5 (4.9) 131.6 (5.2)
Range 113–144 115–142
N (%) of subjects with history of:d
Hyponatremia 148 (96.1) 49 (94.2)
Hyperlipidemia 43 (27.9) 17 (32.7)
Hypertension 126 (81.8) 42 (80.8)
Gastroesophageal reflux disease 82 (53.2) 17 (32.7)
Constipation 63 (40.9) 16 (30.8)
Osteoarthritis 51 (33.1) 13 (25.0)
Depression 61 (39.6) 20 (38.5)
Anxiety 46 (29.9) 11 (21.2)
Insomnia 35 (22.7) 11 (21.2)
Chronic obstructive pulmonary
disease
35 (22.7) 13 (25.0)
Drug hypersensitivity 43 (27.9) 14 (26.9)
Anemia 50 (32.5) 11 (21.2)
Hypothyroidism 41 (26.6) 7 (13.5)
aIncluding native American, Alaskan native, native Hawaiian, Pacific Islander.
bMeasured at local laboratory.
cMeasured at central laboratory.
dCondition reported by X20% of subjects in any group.
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66.7% of subjects who received lixivaptan achieved normal-
ized serum sodium compared with 48.1% of subjects who
received placebo (P¼ 0.017). The results of the local
laboratory analysis demonstrated that lixivaptan subjects
achieved normal serum sodium concentration more rapidly
than placebo (logrank P¼ 0.019). However, time to normal-
ization was not significantly different between treatment
groups based on central laboratory serum sodium results
(logrank P¼ 0.051; Figure 4). Significantly greater percen-
tages of subjects in the lixivaptan group compared with the
placebo group shifted from moderate (4125 and
o130 mmol/l) or severe (p125 mmol/l) hyponatremia at
baseline to normal serum sodium (X135 mmol/l) at day 7
(31.4 (n/n¼ 16/51) vs. 15% (3/20) ; P¼ 0.001) and at the end
of treatment (40.0 (22/55) vs. 27.3% (6/22); P¼ 0.014).
At baseline, 16.9% of subjects in the lixivaptan group and
11.5% in the placebo group were on fluid restriction
(Figure 5). Numerically lower percentages of subjects on
fluid restriction were reported in the lixivaptan-treated group
compared with the placebo group from as early as day 3 until
the end of treatment, with statistically significant differences
observed at weeks 8, 12, 16, and 20.
No significant differences were observed between treat-
ment groups in the percentage of subjects with worsening
hyponatremia at any point in the study, although there was a
trend favoring fewer subjects experiencing worsening hypo-
natremia in the lixivaptan group (57.1% in lixivaptan group
vs. 71.2% in placebo group; P¼ 0.056). The time required to
complete the Trail Making Test, part B (TMT-B) was
significantly improved from baseline to day 28 in subjects
receiving lixivaptan (Po0.001 for baseline vs. day 28 value)
but not in those receiving placebo (P¼ 0.051); however, no
statistically significant differences in TMT-B were observed
between treatment groups. No significant differences were
observed between treatment groups in Medical Outcomes
Survey 6-Item Cognitive Function Scale (MOS-6) scores at
day 28 and week 24; however, significantly greater mean (s.d.)
increases from baseline for MOS-6 scores were observed in
the lixivaptan group compared with the placebo group at
week 8 (7.23 (17.7) vs. 0.62 (13.0); P¼ 0.021) and week 12
(6.21 (18.4) vs. 1.66 (14.6); P¼ 0.047).
Safety
Adverse event profiles in the two treatment groups were
similar for all intratrial comparisons. At least one treatment-
emergent adverse event was experienced by 80.4% of subjects
who received lixivaptan and 84.6% of subjects who received
placebo (Table 2), and the majority of these were mild or
moderate in severity. Adverse events reported by X5%
subjects in the lixivaptan group compared with the placebo
group were urinary tract infection, polyuria, and upper
respiratory tract infection (Table 2). A total of 11.1% subjects
on lixivaptan and 17.3% on placebo had X1 adverse events
leading to study discontinuation. Adverse events that led to
discontinuation in 41 subject in either study group included
septic shock (n¼ 2 (1.3%) with lixivaptan), increased
g-glutamyltransferase (n¼ 2 (1.3%) with lixivaptan), and
flatulence (n¼ 2 (1.3%) with lixivaptan). Serious treatment-
emergent adverse events were reported in 18.3% of subjects
receiving lixivaptan and 26.9% of subjects receiving placebo
(Table 2). Only one serious adverse event, a case of
hyponatremia in the placebo group, was considered by the
investigator to be possibly related to the study drug.
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Seven deaths occurred during the study (six in the lixivaptan
group (3.9%) and one in the placebo group (1.9%)), and one
additional subject in the lixivaptan group died 8 days after the
last recorded dose of the study drug (Table 2). None of the
serious adverse events that led to death were considered by
investigators to be related to the study drug.
At the end of study treatment, more subjects in the
placebo group than in the lixivaptan group had serum
sodium concentrations o125 mmol/l (9.6 vs. 3.3%). On the
basis of central sodium measurements, during the entire
duration of exposure, two (1.3%) lixivaptan subjects and
four (7.7%) placebo subjects had serum sodium concentra-
tions 4145 mmol/l, the predefined level for potential clinical
importance. Only three subjects in the lixivaptan group and
one subject in the placebo group exceeded desirable sodium
correction rates in the first 24 h. No subject experienced an
increase in sodium concentration of 418 mmol/l within a
48- or 72-h period. No subjects had osmotic demyelination
syndrome (ODS) or had symptoms consistent with ODS. No
subject experienced a sodium level of 4155 mmol/l at any
time during the study. No clinically significant changes were
observed in either treatment group for vital signs, 12-lead
electrocardiogram, weight, hematology, biochemistry, or
urinalysis parameters during the study.
DISCUSSION
In this international, multicenter, double-blind, placebo-
controlled, phase III study, once-daily oral lixivaptan safely
and effectively corrected serum sodium concentrations in
outpatients with euvolemic hyponatremia, with significantly
greater effect relative to placebo. This effect was maintained
over the treatment period, despite increased use of fluid
restriction in the placebo group. A greater percentage of
subjects who received lixivaptan (39.4%) achieved normal
serum sodium concentrations after 7 days of treatment
compared with placebo (12.2%). In addition, compared with
placebo, a greater percentage of subjects receiving lixivaptan
had shifted from moderate or severe hyponatremia at baseline
to normal serum sodium after 7 days of treatment (31.4 vs.
15.0%, respectively) and at the end of treatment (40.0 vs.
27.3%, respectively). Discontinuation of lixivaptan at the
conclusion of the treatment period resulted in a decrease in
serum sodium concentrations back toward baseline values,
confirming the chronic nature of the euvolemic hyponatremia
and the therapeutic efficacy of lixivaptan. In analyses of
subgroups, lixivaptan effectively corrected serum sodium
concentrations regardless of sex, age, or baseline serum
sodium concentration. The ability to safely treat elderly
subjects is particularly important, as rates of this condition
increase with age,1 and hyponatremic sequelae such as gait
disturbances are particularly harmful in the elderly.6 The
study, however, was not adequately powered to evaluate
changes in mental state, falls, and other clinical end points.
Given the importance of such assessments, this should be the
target of future trials.
In our study, most adverse events observed with lixivaptan
were mild or moderate and did not lead to disruption of
study medication. As cellular adaptation to chronic hypona-
tremia may occur, patients are at risk for ODS if serum
sodium levels rise too rapidly.23 Current recommendations
call for sodium increases of no more than 12 mmol/l in 24 h
or 18 mmol/l in 48 h.13 Because of the potential risk of ODS, it
was felt important to assess the safety of initiating lixivaptan
in the outpatient setting. In this study, no cases of ODS were
observed, confirming the safety of chronic lixivaptan treat-
ment in this patient population. Only three subjects (2.0%) in
the lixivaptan group and one subject (1.9%) in the placebo
group exceeded the predefined criteria for rapid rise in serum
sodium during the titration phase, and these subjects did not
experience any clinically significant adverse events. The initial
lixivaptan dose (25 mg) allowed for a safe implementation of
treatment in an outpatient setting. Higher doses were used for
treatment initiation in lixivaptan trials requiring hospitaliza-
tion (50 mg). The required assessment of rapidity of change in
Table 2 | Treatment-emergent adverse events in X5% of
subjects, serious adverse events in X2 subjects in either
treatment group, and serious adverse events leading to
death
Treatment-emergent adverse event,
n (%)
Lixivaptan
(n=153)
Placebo
(n=52)
Any adverse event 123 (80) 44 (85)
Urinary tract infection 19 (12) 2 (4)
Headache 12 (8) 7 (14)
Nausea 11 (7) 7 (14)
Diarrhea 10 (7) 4 (8)
Bronchitis 10 (7) 4 (8)
Peripheral edema 10 (7) 4 (8)
Dizziness 10 (7) 2 (4)
Cough 8 (5) 4 (8)
Polyuria 10 (7) 0
Hypertension 9 (6) 1 (2)
Fall 8 (5) 2 (4)
Upper respiratory tract infection 9 (6) 0
Anemia 6 (4) 4 (8)
Vomiting 5 (3) 3 (6)
Hyponatremia 4 (3) 4 (8)
Dehydration 0 3 (6)
Any serious adverse events 26 (17) 14 (27)
Urinary tract infection 4 (3) 2 (4)
Pneumonia 2 (1) 1 (2)
Hyponatremia 3 (2) 2 (4)
Acute cardiac failure 2 (1) 2 (4)
Septic shock 1 (0.7) 0
Grand mal convulsion 0 2 (4)
Serious adverse events leading to death 6 (4) 1 (2)
Acute cardiac failure 0 1 (2)
Myocardial ischemia 1 (0.7) 0
Pneumonia 1 (0.7) 0
Septic shock 1 (0.7) 0
Metastatic small cell lung cancer 1 (0.7) 0
Cerebrovascular accident 1 (0.7) 0
Suicide 1 (0.7) 0
Death from unknown causea 1 (0.7) 0
aThis subject died 8 days after the last recorded dose of study drug and is not
counted in the overall sum of seven deaths but was still considered a treatment-
related adverse event by the investigator.
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serum sodium concentrations 8 h after initiation of therapy
could have been conducted using point-of-care devices, which
would facilitate implementation in settings such as outpatient
clinics and chronic care facilities.
Although an overall favorable safety profile was observed,
a numerically greater incidence of urinary and upper
respiratory infections was reported in lixivaptan-treated
patients in this study. The finding was unexpected and not
easily explainable from a mechanistic point of view. Given the
limited sample size and the number of events, its clinical
relevance is uncertain. More definitive information should
become available after pooling of all lixivaptan clinical trials.
Another randomized, double-blind, placebo-controlled,
phase III study of lixivaptan in hospitalized patients with
euvolemic hyponatremia (LIBRA) was recently completed.24
Compared with subjects in the LIBRA study, the subjects in
the current study had less severe hyponatremia (baseline
serum sodium level of o135 mmol/l in HARMONY vs.
o130 mmol/l in LIBRA). Subjects in the current study
received a lower starting dose of lixivaptan compared with
those in the LIBRA study to allow for steady increases in
serum sodium concentrations in the outpatient setting.
When taken together, the LIBRA and HARMONY trials
support the safety, tolerability, and efficacy of lixivaptan for
the treatment of mild, moderate, and severe hyponatremia
when initiated in either the inpatient or outpatient settings.
Limitations of our study include inability by design to assess
the relationship between improvement of serum sodium and
reduction in symptoms of hyponatremia. In addition, the
study was not powered to assess outcomes such as mortality
and neurological clinical end points.
Among the class of vasopressin V2-receptor antagonists,
tolvaptan was evaluated in two trials: Studies of Ascending
Levels of Tolvaptan in Hyponatremia 1 and 2 (SALT1 and
SALT2).18 These studies enrolled hypervolemic (congestive
heart failure and liver cirrhosis) and euvolemic (SIADH)
hyponatremic subjects for a 30-day double-blind, placebo-
controlled study period (SALT1: n¼ 108; SALT2: n¼ 243).
The studies achieved their primary co-endpoints of signifi-
cantly increased change over placebo in daily sodium AUC
from baseline to day 4 and from baseline to day 30. Although
direct comparison between HARMONY and SALT1/SALT2
cannot be made, three key differences in study design warrant
discussion: SALT1 and SALT2 excluded subjects with symp-
toms of hyponatremia, whereas HARMONY allowed subjects
with symptoms (other than severe symptoms such as seizures
and coma); the SALT studies excluded enrollment of subjects
with a baseline serum sodium o120 mmol/l accompanied
with neurological manifestations, whereas HARMONY allowed
subjects with more severe hyponatremia; and finally, SALT1/
SALT2 required hospitalization of subjects for a minimum of
3 days after randomization, whereas HARMONY recruited
and treated subjects in outpatient settings.
In conclusion, once-daily oral lixivaptan given in an
outpatient setting increased serum sodium concentrations
in subjects with euvolemic hyponatremia in a gradual,
well-tolerated manner, separating significantly from placebo
by day 3. An open-label extension of this study is ongoing to
further define long-term efficacy and safety.
MATERIALS AND METHODS
Subjects
Subjects aged X18 years with a diagnosis of chronic euvolemic
hyponatremia (serum sodium o135 mmol/l within 24 h of study
entry) were eligible to participate in the study. Patients with
symptoms associated with hyponatremia were allowed to participate,
provided that their symptoms did not require immediate interven-
tion (e.g., seizures or coma). Patients with acute or transient
hyponatremia, pseudohyponatremia, hypovolemic hyponatremia,
drug-induced hyponatremia, hyponatremia due to hypothyroidism
or adrenal insufficiency, hypertonic hyponatremia, or hypokalemia
were excluded. Other key exclusion criteria were as follows: treatment
for hyponatremia with demeclocycline, lithium carbonate, urea, or
any other vasopressin antagonist within 7 days of participation,
supine systolic arterial blood pressurep90 mm Hg, serum creatinine
43.0 mg/dl, uncontrolled diabetes, liver disease, psychogenic poly-
dipsia, urinary tract obstruction, or myocardial ischemia, myocardial
infarction, or cerebrovascular accident within 30 days of enrollment,
neurological impairments such as dementia, and conditions causing
an inability to respond to thirst. Women who were pregnant,
planning to become pregnant, or breastfeeding were also excluded.
The HARMONY study protocol was approved by the Institutional
Review Board or Independent Ethics Committee at the participating
sites and was conducted in accordance with the ethical principles of
the Declaration of Helsinki and the International Conference on
Harmonisation guidelines for Good Clinical Practice. All subjects
provided written informed consent to participate.
Study design
The HARMONY study (ClinicalTrials.gov. identifier:
NCT00876798) was a multicenter randomized, double-blind,
placebo-controlled, phase III study conducted at 61 sites enrolling
in eight countries (Belgium, Czech Republic, Israel, India, Italy,
Mexico, Peru, and the United States). Eligible subjects were
randomized 3:1 to 25 mg lixivaptan or matched placebo given in
the morning as an oral capsule with or without food. Following
administration of the first dose, serum sodium was retested at 8 h;
subjects with changes of o8 mmol/l were scheduled to return for
assessments at 24 and 48 h following treatment initiation for
possible uptitration. Subjects with an initial change in serum
sodium concentration X8 mmol/l were expected to be kept under
observation and follow-up measurements to be conducted at 12, 24,
48, and 72 h post dose or until sodium levels had stabilized.
The daily lixivaptan dose was 25, 50, or 100 mg, titrated based on
serum sodium levels. Titration was based on the following criteria:
subjects whose serum sodium changed by o5 mmol/l in a 24-h
period were eligible to be titrated to the next highest dose level if
their sodium levels were o135 mmol/l, and subjects with serum
sodium changesX5 mmol/l were maintained at the current dose or
had their dose decreased to maintain serum sodium concentrations
of 135–145 mmol/l; treatment was downtitrated or stopped in
subjects whose serum sodium concentrations changed 412 mmol/l
within 24 h or 418 mmol/l within 48 h, those whose serum sodium
was 4145 mmol/l, or who experienced symptoms of over-rapid
sodium correction. Investigators were encouraged, when clinically
appropriate, not to institute fluid restriction during the first 72 h of
study drug administration to allow for assessment of treatment
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effect on serum sodium concentrations; fluid restriction could be
implemented, maintained, or adjusted at the investigator’s discre-
tion during the entire treatment period. A 24-week treatment period
was planned. This was followed by a 7-day post-treatment visit and a
telephone follow-up 30 days after subject discontinuation or at the
end of the study.
Study assessments
The primary study end point was the change from baseline in serum
sodium concentration at day 7. Secondary end points were as
follows: the change in the normalized AUC of serum sodium from
baseline to week 4, the percentage of subjects with normalized
sodium at day 7 (135–145 mmol/l inclusive), the percentage of
subjects who required fluid restriction after baseline, the number of
subjects with worsening hyponatremia (reduction in serum sodium
concentration of X3 mmol/l from the preceding measurement and
serum sodiumo135 mmol/l), and the change from baseline to week
4 in time required to complete the TMT-B. MOS-6 scores at week 4
and week 24 were an exploratory end point.
Serum sodium was assessed on site without delay by local
laboratories or with a point-of-care device to direct the titration of
study medication as noted above. However, a central laboratory was
used to measure serum sodium concentrations for the assessment of
efficacy variables, unless otherwise noted. In addition to serum
sodium, standard hematology, biochemistry, and urinalysis were
performed at each visit. Visits occurred at baseline, on days 1, 2, 3,
and 4, within 2 days of day 7, and weeks 2, 3, 4, 8, 12, 16, 20, and 24.
The TMT-B, a performance-based measure of motor speed and visual
attention, was administered at baseline and weeks 4 and 24 (or early
termination visit). The MOS-6, a six-item cognitive function survey,
was administered at weeks 4, 8, 12, 16, 20, and 24 (or at early
termination visit).
Physical examination, 12-lead electrocardiogram, weight, and
vital signs were recorded during study visits at screening and at
regular intervals. Adverse events were recorded at each visit and were
treated in the inpatient setting where necessary until resolution.
Subjects could report adverse events to their investigators throughout
the study. Fluid restriction, use of diuretics, and daily fluid
requirements were also recorded.
Statistical analyses
A sample size of 200 (150 in lixivaptan group and 50 in the placebo
group) was determined to allow for 80% power to detect a mean
difference of 3.7 mmol/l between treatment groups using a two-sided
t-test at the 0.05 significance level. These values were based on those
used in the SALT 1 and SALT 2 trials,18 which reported data for day 4
and day 11. However, no information was available for day 7, the time
point for the HARMONY trial primary end point. Hence, for sample
size calculations for the HARMONY trial, day 4 values from the SALT
studies were used in place of day 7. The value of 3.7 mmol/l for the
differential change from baseline is also consistent with Schrier
et al.,18 allowing for inclusion of subjects with mild hyponatremia.
Efficacy analyses were performed for the ITT population, which
included all randomized subjects. Secondary efficacy analyses were
also performed for a modified ITT population, which consisted of
all randomized subjects who had received at least one dose of the
study drug, had a baseline serum sodium measurement, and had at
least one recorded postbaseline serum sodium measurement while
on the study drug.
The primary efficacy variable was analyzed using analysis of
covariance, with treatment and pooled site as factors and baseline
serum sodium as the covariate. The primary analysis was based on the
change from baseline at day 7 in central sodium concentrations from
the ITT population using last observation carried forward/next
observation carried back (LOCF/NOCB) as the imputation method
for missing observations. Subjects in the modified ITT and ITT
subgroups, based on age, sex, race, and baseline local serum sodium
levels, were analyzed for the primary efficacy variable. Sensitivity
analyses were also performed using central laboratory or local sodium
measurements, including baseline observation carried forward, OV,
and mixed effects model repeated measures analyses of the ITT
population and OV analysis of the modified ITT population.
The ITT population was analyzed using LOCF/NOCB for all
secondary end points and central sodium values were used where
applicable. The secondary end points of time-normalized AUC
change from baseline and time to complete the TMT-B were
analyzed using analysis of covariance as for the primary variable. As
sensitivity analyses, AUC change from baseline was also analyzed for
the ITT population using OV and LOCF/NOCB for central and local
sodium, and for the modified ITT population using OV for central
sodium and LOCF/NOCB for central and local sodium. The other
secondary end points (subjects with normalized serum sodium
concentration, subjects requiring fluid restriction, and subjects
with worsening hyponatremia) were analyzed using the Cochran–-
Mantel–Haenszel test controlling for pooled site.
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